Biobeat introduces innovative blood pressure monitoring wearable

By Nikita Chaurasia  Date: 2021-05-28

Biobeat introduces innovative blood pressure monitoring wearable

Israel-based wearable remote patient-monitoring solutions provider Biobeat has recently unveiled a new wearable and continuous ABPM (ambulatory blood pressure monitoring) chest-monitoring device.

Knowledgeable sources cited that ABPM can serve as a definitive indicator of patient health, collecting patient cardiac data continually in real-life settings outside of the physician's office to provide an authentic, holistic, and impartial perspective of patient health.

This device is the only cuff-less ABPM application in the world, transforming the logistical workflow of the ABPM test, as every disposable, sterile monitor is sent to the patient's house by courier.

Arik Ben Ishay, CEO of Biobeat, on the matter, expressed that the use of ABPM solutions has increased throughout the healthcare spectrum as the industry is undergoing a digital transformation, and this trend will continue as they advance towards the post-COVID-19 age.

Trusted sources cited that the patient self-setup feature of the company’s disposable wearable chest monitor is simple and intuitive, which exempts assistance from a doctor or specialist.

The device measures mean arterial pressure, heart rate, systemic vascular resistance, cardiac output, along with systolic and diastolic blood pressure, sources cited. These critical metrics are then available to patients via a dedicated app on their mobile phone and are also accessible to clinicians via an online report-analysis web application.

The report allows healthcare workers to acquire a deep understanding of the fundamental cause of the concerns reported by leveraging the data on a wide range of vital signs collected by the Biobeat device, allowing for a more precise prescription and evaluation of medications and therapies.

Professor Arik Eisenkraft, MD, Chief Medical Officer at Biobeat, mentioned the clinical trial highlights the advantages of their device over cuff-based ABPM devices, with ease-of-use and lack of bias stemming from the mechanical effects of the inflating cuff. 

The results also showed that traditional cuff-based ABPM devices resulted in higher blood pressure readings, most likely due to a startling effect generated by the inflated cuff and Biobeat's wireless wrist monitor was substantially less inconvenient than the cuff-based device.

Source Credits –

https://www.prnewswire.com/il/news-releases/biobeat-launches-wearable-continuous-ambulatory-blood-pressure-monitoring-abpm-device-823072614.html

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Netflix confirms producing fictionalized version of Spotify’s ascension

Netflix confirms producing fictionalized version of Spotify’s ascension

By Nikita Chaurasia

Over-the-top content streaming & production giant Netflix Inc. is reportedly working on an untitled series that tells the story of one of the most successful music streaming companies, Spotify Ltd. The six-part series, already listed on Netflix,...

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

Edtech Byju’s is now India’s highest-valued startup at USD 16.5 billion

By Nikita Chaurasia

Byju’s, the largest education technology company, has emerged as India’s highest-valued startup after a USD 340 million funding round involving investors such as UBS Group, Blackstone, and Zoom founder Eric Yuan among others. Recently, B...

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

LiDAR maker Hesai Photonics secures USD 300 million in Series D funding

By Nikita Chaurasia

Hesai Photonics Technology Co. Ltd., a leading Shanghai-based LiDAR company, has reportedly secured USD 300 million in a Series D funding round which was led by GL Ventures LLC, Xiaomi Corporation, Hillhouse Capital Group, Meituan, and CPE. The roun...

Tesla terminates production of its Model S Plaid + variant indefinitely

Tesla terminates production of its Model S Plaid + variant indefinitely

By Nikita Chaurasia

CEO Elon Musk justified Model S Plaid as good enough against its successor. The Model S Plaid + was touted to be Tesla’s flagship vehicle, with a range of around 519 miles. After unveiling for the first time last year, American EV maker T...

ByHeart concludes largest U.S. clinical trial for infant food product

ByHeart concludes largest U.S. clinical trial for infant food product

By Nikita Chaurasia

ByHeart Inc., a New-York based infant, and baby nutrition company, has recently announced the completion of the largest clinical trial for new infant formula in the past 25 years. With this move, the company is earmarked to be the 4th FDA registered,...